RISPERDAL by Johnson & Johnson is unclear. Approved for schizophrenia, acute manic, mixed episodes associated with bipolar i disorder and 5 more indications. First approved in 2003.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
RISPERDAL (risperidone) is an atypical antipsychotic approved in 2003 for schizophrenia, bipolar disorder, and irritability associated with autism spectrum disorder. It works by antagonizing dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances. Available as oral tablets and orally disintegrating formulations for flexible dosing.
LOE-stage product with minimal commercial growth; career roles focus on lifecycle management, generic transition planning, and selective market defense rather than expansion.
unclear. The drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite,…
Worked on RISPERDAL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
Bioavailability of LY03004 and Risperdal® Consta®
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
Bioequivalence Test for Risperdal 2mg of Janssen Korea
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on RISPERDAL at LOE stage offers limited growth career momentum but valuable experience in lifecycle management, generic transition, and portfolio optimization within a mature therapeutic category. Roles emphasize defending market share and extracting residual value rather than driving expansion.